A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease

201578 citationsJournal Article

Authors

Ralf Reilmann · Hertie Institute for Clinical Brain Research

Marie‐Laure Rouzade‐Dominguez · Novartis (Switzerland)

Carsten Saft · St. Josef-Hospital

Sigurd D. Süßmuth · Universität Ulm

Josef Priller · Charité - Universitätsmedizin Berlin

Anne Rosser · Cardiff University

Hugh Rickards

Abstract

AFQ056 did not reduce choreatic movements in HD, but was well tolerated. The clinical relevance of the Q-Motor findings (speeded-tapping) are unknown and may warrant further investigation.

Topics & Keywords

Genetic Neurodegenerative Diseases Neurological disorders and treatments Neurology and Historical Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Movement Disorders

Volume 30, Issue 3, pp. 427-431

DOI: 10.1002/mds.26174

Field-Weighted Citation Impact: 5.32